Evidence map›Paper›PMID 25002612›Full record

ArticleCancer discovery2014

SPSB1 may have MET its match during breast cancer recurrence.

Yuanbo Qin, Sandra S McAllister

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer discovery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. c-MET expression potentially contributes to the poor prognosis of rhabdomyosarcoma.International journal of clinical and experimental pathology · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yuanbo QinAuthors' Affiliations:Hematology Division, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School;
Sandra S McAllisterAuthors' Affiliations:Hematology Division, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School; Harvard Stem Cell Institute, Boston; and Broad Institute of Harvard and MIT, Cambridge, Massachusetts smcallister1@partners.org.
Brigham and Women's Hospital · US

Funding

Understanding How Breast Cancers Activate and Respond to the Systemic EnvironmentR01CA166284 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI MCALLISTER, SANDRA S · 2012 to 2018
$2.2M
NCI NIH HHS R01 CA166284
6 · The paper itself

Abstract

summaryDisease recurrence is the most common cause of death for patients with breast cancer, yet little is known about the molecular mechanisms underlying this process. Using inducible transgenic mouse model systems, Feng and colleagues identified SPSB1 as a determinant of breast cancer recurrence by virtue of its ability to protect tumor cells from apoptosis through c-MET activation.

Indexed as

AnimalsBreast NeoplasmsFemaleHumansNeoplasm Recurrence, LocalProto-Oncogene Proteins c-metSuppressor of Cytokine Signaling ProteinsProto-Oncogene Proteins c-metSuppressor of Cytokine Signaling Proteins

Identifiers

PMID25002612
PMCPMC4090600
OpenAlexW2098068149

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.